Analyst Downgrades: Shoe Carnival, Inc., Amicus Therapeutics, Inc., and Nivalis Therapeutics Inc

Analysts downwardly revised their ratings and price targets on Shoe Carnival, Inc. (NASDAQ:SCVL), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Nivalis Therapeutics Inc (NASDAQ:NVLS)

Nov 29, 2016 at 9:20 AM
facebook twitter linkedin

Analysts are weighing in on footwear retailer Shoe Carnival, Inc. (NASDAQ:SCVL), as well as biotech stocks Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Nivalis Therapeutics Inc (NASDAQ:NVLS). Here's a quick roundup of today's bearish brokerage notes on SCVL, FOLD, and NVLS.

  • SCVL is on pace to open 15% lower, after the company posted a disappointing third-quarter earnings report and lowered its full-year outlook. Jefferies responded with a price-target cut to $28 from $29. The pending move would put Shoe Carnival, Inc. -- which closed Monday at $30.27 -- well below the round $30 level that acted as resistance earlier in the year. However, the stock remains comfortably above its year-to-date breakeven level of $23.20 for the time being. In the options pits, it appears SCVL traders were bracing for a pullback. Data shows put buying more than tripled call buying during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). 

  • Analysts are cutting their expectations on FOLD, after the Food and Drug Administration (FDA) said it needed more data for the company's Fabry disease treatment, migalastat, before granting approval. At least five brokerage firms have since slashed their price targets, with the lowest mark of $7 coming from Baird. After closing Monday at $8.32, Amicus Therapeutics, Inc. is now set to lose roughly one-quarter of its value out of the gate, and open at its lowest price since early November. FOLD is vulnerable to additional bearish notes, too, since five of six analysts rate the shares a "strong buy," and none consider them a "sell." 

  • NVLS has given back over half its value in electronic trading, following news the drugmaker's cystic fibrosis treatment did not meet its goals in a mid-stage study. No fewer than five analysts have downgraded the stock as a result, with Stifel cutting its outlook to "hold" from "buy," and lowering its price target to $3.25 from $16 -- a deep discount to Monday's settlement at $6.25. All of this has Nivalis Therapeutics Inc on pace to open at all-time lows, and like FOLD, the shares could be pressured lower by forthcoming bearish attention from the brokerage bunch. Not only do all five covering analysts recommend buying NVLS, but its average 12-month price target comes in at $14.06, territory not explored in over a year.
Find out where the Dow lands right after the closing bell. Sign up now for Schaeffer's Market Recap

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners